Long-Term Use of Contraceptive Depot Medroxyprogesterone Acetate in Young Women Impairs Arterial Endothelial Function Assessed by Cardiovascular Magnetic Resonance

Background—Depot medroxyprogesterone acetate (DMPA) inhibits proliferation of ovarian follicles, resulting in anovulation and a decrease in circulating estrogen; the latter action is potentially disadvantageous to cardiovascular health. We therefore investigated the vascular effects of long-term contraceptive DMPA in young women. Methods and Results—Endothelium-dependent (hyperemia-induced flow-mediated dilatation [FMD]) and -independent (glyceryl trinitrate [GTN]) changes in brachial artery area were measured using cardiovascular magnetic resonance in 13 amenorrheic DMPA users (>1 year use; mean age 29±4 years) and in 10 controls (mean age 30±4 years, P =0.25) with regular menstrual cycles after validation of the technique. FMD and GTN responses were measured just before repeat MPA injection and 48 hours later (n=12) in DMPA users and during menstruation and midcycle (n=9) in controls. Serum-estradiol levels (S-estradiol) were measured at both visits. FMD was reduced in DMPA users compared with controls during menstruation (1.1% versus 8.0%, respectively P <0.01) without differences in GTN responses. S-estradiol levels in DMPA users were significantly lower than in controls during menstruation (58 versus 96 pmol/L, P <0.01). High levels of circulating MPA 48 hours after injection were not linked to an additional impairment in FMD (2.0% versus 3.1%, P =0.23). Estradiol levels were significantly correlated to FMD (r =0.43, P <0.01). Conclusions—Endothelium-dependent arterial function measured by cardiovascular magnetic resonance is impaired in chronic users of DMPA, and hypoestrogenism may be the mechanism of action. DMPA might adversely affect cardiovascular health, and in particular its use in women with cardiovascular disease should be additionally evaluated.

[1]  A. Wakatsuki,et al.  Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. , 2003, Circulation.

[2]  M. Watkins,et al.  Risk Stratification for Postoperative Cardiovascular Events via Noninvasive Assessment of Endothelial Function: A Prospective Study , 2002, Circulation.

[3]  A. Wakatsuki,et al.  Effect of Medroxyprogesterone Acetate on Endothelium-Dependent Vasodilation in Postmenopausal Women Receiving Estrogen , 2001, Circulation.

[4]  C. Hayward,et al.  Tamoxifen is not detrimental to endothelial function in postmenopausal women with breast cancer. , 2001, American heart journal.

[5]  V. Rickert,et al.  A Prospective, Controlled Study of the Effects of Hormonal Contraception on Bone Mineral Density , 2001, Obstetrics and gynecology.

[6]  M. Sowers,et al.  Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. , 2001, Fertility and sterility.

[7]  A. Lusis,et al.  Testosterone inhibits early atherogenesis by conversion to estradiol: Critical role of aromatase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  K. Kugiyama,et al.  Effect of medroxyprogesterone acetate plus estradiol on endothelium-dependent vasodilation in postmenopausal women. , 2001, The American journal of cardiology.

[9]  A. Meier,et al.  Depomedroxyprogesterone‐induced Hypoestrogenism and Changes in Vaginal Flora and Epithelium , 2000, Obstetrics and gynecology.

[10]  D J Pennell,et al.  Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? , 2000, European heart journal.

[11]  C. Delles,et al.  Effects of oral contraceptives on vascular endothelium in premenopausal women. , 2000, American journal of obstetrics and gynecology.

[12]  R. Cannon,et al.  Oral L-arginine in patients with coronary artery disease on medical management. , 2000, Circulation.

[13]  A M Zeiher,et al.  Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. , 2000, Circulation.

[14]  S. Higano,et al.  Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. , 2000, Circulation.

[15]  R. Karas,et al.  The protective effects of estrogen on the cardiovascular system. , 2002, The New England journal of medicine.

[16]  C. Hayward,et al.  Effect of fat and carbohydrate consumption on endothelial function , 1999, The Lancet.

[17]  R. Cannon,et al.  Vascular effects of estrogen and vitamin E therapies in postmenopausal women. , 1999, Circulation.

[18]  C. Webb,et al.  Estrogen hits the surface , 1999, Nature Medicine.

[19]  D. Horsfall,et al.  Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells , 1999, Molecular and Cellular Endocrinology.

[20]  A. Chang,et al.  Prospective randomized study of the effect of "add-back" hormone replacement on vascular function during treatment with gonadotropin-releasing hormone agonists. , 1998, Circulation.

[21]  P. Ganz,et al.  Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. , 1998, Circulation.

[22]  P. Fletcher,et al.  Reproducibility of brachial ultrasonography and flow-mediated dilatation (FMD) for assessing endothelial function. , 1997, Australian and New Zealand journal of medicine.

[23]  J. Rösch,et al.  Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm , 1997, Nature Medicine.

[24]  C. Stehouwer,et al.  Modulation of endothelium-dependent, flow-mediated dilatation of the brachial artery by sex and menstrual cycle. , 1996, Circulation.

[25]  S. Nakao,et al.  Non-invasive detection of endothelial dysfunction with 30 MHz transducer , 1996, The Lancet.

[26]  D. Mishell Pharmacokinetics of depot medroxyprogesterone acetate contraception. , 1996, The Journal of reproductive medicine.

[27]  M. Frederiksen Depot medroxyprogesterone acetate contraception in women with medical problems. , 1996, The Journal of reproductive medicine.

[28]  J. K. Lloyd,et al.  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis , 1992, The Lancet.

[29]  L. Enk,et al.  A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. , 1992, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[30]  I. Reid,et al.  Bone density in women receiving depot medroxyprogesterone acetate for contraception. , 1991, BMJ.

[31]  S. Moncada,et al.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.

[32]  R. Furchgott,et al.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.